How to buy Viking Therapeutics shares

Own Viking Therapeutics shares in just a few minutes.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Viking Therapeutics, Inc is a biotechnology business with stocks listed in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$5.26 – an increase of 0.38% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Viking Therapeutics

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Viking Therapeutics. Find the share by name or ticker symbol: VKTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Viking Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$5.26, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Viking Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Viking Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Viking Therapeutics share price

Use our graph to track the performance of VKTX stocks over time.

Viking Therapeutics shares at a glance

Information last updated 2021-06-10.
52-week rangeUS$5.12 - US$10.09
50-day moving average US$5.8271
200-day moving average US$6.4742
Target priceUS$18.92
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-0.353

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Viking Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Viking Therapeutics price performance over time

Historical closes compared with the last close of $5.26

1 week (2021-06-03) -0.19%
1 month (2021-05-12) -11.15%
3 months (2021-03-12) -22.07%
6 months (2020-12-11) -16.38%
1 year (2020-06-12) -27.45%
2 years (2019-06-12) -34.09%
3 years (2018-06-12) -48.58%
5 years (2016-06-10) 298.48%

Viking Therapeutics financials

Gross profit TTM US$0
Return on assets TTM -10.89%
Return on equity TTM -17.34%
Profit margin 0%
Book value 3.074
Market capitalisation US$436.6 million

TTM: trailing 12 months

Shorting Viking Therapeutics shares

There are currently 10.2 million Viking Therapeutics shares held short by investors – that's known as Viking Therapeutics's "short interest". This figure is 5.7% down from 10.8 million last month.

There are a few different ways that this level of interest in shorting Viking Therapeutics shares can be evaluated.

Viking Therapeutics's "short interest ratio" (SIR)

Viking Therapeutics's "short interest ratio" (SIR) is the quantity of Viking Therapeutics shares currently shorted divided by the average quantity of Viking Therapeutics shares traded daily (recently around 818131.58742949). Viking Therapeutics's SIR currently stands at 12.41. In other words for every 100,000 Viking Therapeutics shares traded daily on the market, roughly 12410 shares are currently held short.

However Viking Therapeutics's short interest can also be evaluated against the total number of Viking Therapeutics shares, or, against the total number of tradable Viking Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viking Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Viking Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1622% of the tradable shares (for every 100,000 tradable Viking Therapeutics shares, roughly 162 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Viking Therapeutics.

Find out more about how you can short Viking Therapeutics stock.

Viking Therapeutics share dividends

We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.

Viking Therapeutics share price volatility

Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as US$5.12 up to US$10.09. A popular way to gauge a stock's volatility is its "beta".

VKTX.US volatility(beta: 1.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 1.8424. This would suggest that Viking Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viking Therapeutics overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform